John Parkinson

Basilea Pharmaceutica says its investigational therapy, fosmanogepix, is being studied for candidemia and invasive candidiasis.

Moderna has begun its study examining its investigational norovirus vaccine, mRNA-1403, to determine its efficacy, safety and immunogenicity.

Jennifer Quinn, head of Global Value & Access, Debiopharm, offers insights on pull incentives and how they look to get more antibiotics to market.

The Centers for Disease Control and Prevention (CDC) says a return to normalcy and vaccination protection waning are likely causes.

The CDC reports 59 listeriosis cases and 10 deaths across 19 states, urging vulnerable populations to avoid deli meats, especially Boar's Head liverwurst.

A novel test is looking to ascertain this diagnostic information quickly to aid clinicians in making a determination of infections and more efficiently prescribe antimicrobials.

With 26 cases confirmed and several fatalities, the African country is experiencing its first bout of the zoonotic disease.

Study finds this population saw a 45% reduction of ongoing symptoms in those with COVID-19 weeks later and who had received subsequent doses of the original monovalent vaccine.

The latest data highlight ibezapolstat’s effects on gut microbiome health and systemic exposure, crucial for CDI treatment, while also indicating its potential against Bacillus anthracis, prompting plans for a bioterrorism development initiative.

An English modeling study suggests level of protection decreases only very slightly over time and reminds parents to have their children up to date on all vaccinations.

The findings are from a National Foundation for Infectious Diseases (NFID) survey showing many Americans are not thinking about flu, COVID-19, RSV, or pneumococcal disease, and many respondents do not plan to get vaccinated this fall.

Maryann Webb’s harrowing, personal experience with C diff, along with her professional work with federal agencies has prepared her for a life in advocacy with the Peggy Lillis Foundation. She wants to see the fecal microbiota transplant become more accessible and is working with Congress to make the infection a notifiable infectious disease.

The federal agency offers guidance for US clinicians and travelers to understand the disease better and employ preventative measures to reduce incidence rates.

Ammara Mushtaq, MD, discusses the underrepresentation of different races during the pandemic, but also the newer efforts to include and represent these communities in smaller, local studies.

A new survey reveals that infectious disease virologists, epidemiologists and clinicians see the need to address gaps in surveillance programs to identify emerging pathogens, public health funding and testing infrastructure capabilities.

Jeanine Thomas, president and founder of MRSA Survivors Network, talks about her personal battle with osteomyelitis, her work as an advocate, and the need for data and awareness to bring it to the forefront again.

Katrine Wallace, PhD, and Eric John Burnett, MD, discuss the distinctions between them and strategies to understand better the information people are consuming.

A large study shows a moderate benefit to taking the antimalarial therapy.

New predictive statistical modeling shows that antimicrobial resistance (AMR) deaths will rise steadily in the coming decades.

The CSL and Arcturus Therapeutics’ vaccine, ARCT-154 (Kostaive), is designed to offer protection against the JN1 strain.

The International Society for Infectious Diseases (ISID) ProMED surveillance system is a way for clinicians and interested ID stakeholders to be aware of local outbreaks and follow-up in response to get more information on them.

The organization's designation for the Bavarian Nordic’s MVA-BN (Jynneos) mpox vaccine is aimed at helping with the public health response, especially in Africa, where incidences rates continue to increase.

Ami Patel, PhD, provides insights on both technologies and how her research center, the Wistar Institute, is involved in DNA vaccine and monoclonal antibody research.

Gilead’s HIV-1 capsid inhibitor, which is a twice-yearly injection, was more effective than a daily Truvada pill in a phase 3 trial.

Crestone’s novel therapy, CRS3123, demonstrated 97% clinical cure rate in small phase 2 study.

Kevin Nguyen, PharmD, offers some insights on some of the challenges in the outpatient setting with regards to stewardship, and novel strategies being utilized.

Our panel discusses this patient group and the challenges associated with their care.

Debra Goff, PharmD, discusses her advocacy around this topic and bringing the stewardship message to dentists about how antibiotic prescribing practices have changed and getting them to recalibrate their thinking and actions in their field.

Benjamin Park, MD, offers insights on the federal agency’s role in AMR.

Jennifer Ronholm, PhD, discusses the novel concept of microbiome protection to create healthier animals and reduce antimicrobial usage.